AU2012321074B2 - Measurement of autoantibodies at low conductivity conditions with increased sensitivity - Google Patents

Measurement of autoantibodies at low conductivity conditions with increased sensitivity Download PDF

Info

Publication number
AU2012321074B2
AU2012321074B2 AU2012321074A AU2012321074A AU2012321074B2 AU 2012321074 B2 AU2012321074 B2 AU 2012321074B2 AU 2012321074 A AU2012321074 A AU 2012321074A AU 2012321074 A AU2012321074 A AU 2012321074A AU 2012321074 B2 AU2012321074 B2 AU 2012321074B2
Authority
AU
Australia
Prior art keywords
conductivity
less
autoantibody
amyloid
autoantibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012321074A
Other languages
English (en)
Other versions
AU2012321074A1 (en
Inventor
Andrea ENGELMAIER
Hans-Peter Schwarz
Alfred Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2012321074A1 publication Critical patent/AU2012321074A1/en
Assigned to Baxalta GmbH, BAXALTA INCORPORATED reassignment Baxalta GmbH Request for Assignment Assignors: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
Application granted granted Critical
Publication of AU2012321074B2 publication Critical patent/AU2012321074B2/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: Baxalta GmbH, BAXALTA INCORPORATED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2012321074A 2011-12-13 2012-12-13 Measurement of autoantibodies at low conductivity conditions with increased sensitivity Active AU2012321074B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161570211P 2011-12-13 2011-12-13
US61/570,211 2011-12-13
PCT/US2012/069587 WO2013090636A1 (en) 2011-12-13 2012-12-13 Measurement of autoantibodies at low conductivity conditions with increased sensitivity

Publications (2)

Publication Number Publication Date
AU2012321074A1 AU2012321074A1 (en) 2013-06-27
AU2012321074B2 true AU2012321074B2 (en) 2015-12-03

Family

ID=47630506

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012321074A Active AU2012321074B2 (en) 2011-12-13 2012-12-13 Measurement of autoantibodies at low conductivity conditions with increased sensitivity

Country Status (14)

Country Link
US (1) US9075069B2 (enExample)
EP (1) EP2791675B1 (enExample)
JP (1) JP6333731B2 (enExample)
KR (1) KR20140104479A (enExample)
AR (1) AR089233A1 (enExample)
AU (1) AU2012321074B2 (enExample)
DK (1) DK2791675T3 (enExample)
ES (1) ES2685332T3 (enExample)
HR (1) HRP20181118T1 (enExample)
HU (1) HUE038441T2 (enExample)
PL (1) PL2791675T3 (enExample)
PT (1) PT2791675T (enExample)
TW (1) TW201339578A (enExample)
WO (1) WO2013090636A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
EP3022225B1 (en) * 2013-07-19 2021-09-29 Board Of Regents Of the University Of Texas System Transthyretin amyloid-selective and polyreactive catabodies
SI24638A (sl) 2014-02-04 2015-08-31 Univerzitetni kliniÄŤni center Ljubljana Fluorometrična imunska metoda za določanje protiteles proti dvojnoverižni DNA
BR112017002575B1 (pt) * 2014-08-08 2023-11-07 Allegheny Singer Research Institute Método para diagnosticar especificamente lúpus sistêmico eritematoso em um indivíduo
JP6674543B2 (ja) 2015-07-31 2020-04-01 アレゲーニー・シンガー リサーチ インスティチュート 抗体に基づく薬物のコンパニオン診断としての細胞結合補体活性化産物アッセイ
KR20170108203A (ko) 2016-03-16 2017-09-27 주식회사 피플바이오 응집형-형성 폴리펩타이드의 응집형을 검출하는 방법
CN108169303B (zh) * 2017-12-07 2019-08-20 商丘师范学院 基于金属有机框架材料作为信号探针的核酸适配体电化学传感器
WO2020010009A1 (en) * 2018-07-02 2020-01-09 Siemens Healthcare Diagnostics Inc. Direct immunoassay measurement of autoantibodies
JP7268306B2 (ja) * 2018-08-31 2023-05-08 東洋紡株式会社 生体試料中の測定対象物質を免疫学的に測定する方法
JP7356128B2 (ja) * 2019-06-07 2023-10-04 慶應義塾 自己免疫疾患の検出剤となるタンパク質複合体、及びその使用
CN113759107A (zh) * 2021-08-18 2021-12-07 苏州立禾生物医学工程有限公司 生物素标记缓冲液

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0064275A1 (en) * 1981-05-02 1982-11-10 Mitsubishi Kasei Corporation Immunochemical reagent

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259207A (en) * 1979-09-19 1981-03-31 American Hospital Supply Corporation Suspending medium for immunologic reactions
US5183735A (en) * 1989-02-27 1993-02-02 Reaads Medical Products, Inc. Method and diagnostic test kit for detection of anti-dsDNA antibodies
US5194585A (en) * 1989-04-25 1993-03-16 Igen, Inc. Inhibitors of catalytic antibodies
US5981180A (en) 1995-10-11 1999-11-09 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
US5763158A (en) 1997-02-06 1998-06-09 The United States Of America As Represented By The Secretary Of The Army Detection of multiple antigens or antibodies
US6958244B2 (en) * 2002-04-12 2005-10-25 Bruker Biospin Corp. Low-conductivity buffers for magnetic resonance measurements
WO2005027714A2 (en) * 2003-07-12 2005-03-31 Accelr8 Technology Corporation Sensitive and rapid biodetection
EP2522753B1 (en) 2007-08-13 2014-04-02 Baxter International Inc. IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease
US8852874B2 (en) 2008-02-29 2014-10-07 Baxter International Inc. Anti-amyloid β activity of intravenous immunoglobulin (IVIG) in vitro
EP2418486B1 (en) * 2009-03-05 2013-11-06 Denka Seiken Co., Ltd. Test reagent kit and its use in a method for measuring an analyte in test sample
TW201040529A (en) * 2009-03-31 2010-11-16 Japan Tobacco Inc Method for detecting antibody against SITH-1 in biological sample
BRPI1012082B1 (pt) 2009-05-27 2022-08-16 Takeda Pharmaceutical Company Limited Método para preparar uma composição de igg concentrada a partir de plasma
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0064275A1 (en) * 1981-05-02 1982-11-10 Mitsubishi Kasei Corporation Immunochemical reagent

Also Published As

Publication number Publication date
HUE038441T2 (hu) 2018-10-29
HRP20181118T1 (hr) 2018-09-21
JP6333731B2 (ja) 2018-05-30
JP2015500502A (ja) 2015-01-05
KR20140104479A (ko) 2014-08-28
ES2685332T3 (es) 2018-10-08
PL2791675T3 (pl) 2018-10-31
EP2791675B1 (en) 2018-04-25
US20130149700A1 (en) 2013-06-13
EP2791675A1 (en) 2014-10-22
WO2013090636A1 (en) 2013-06-20
PT2791675T (pt) 2018-07-27
TW201339578A (zh) 2013-10-01
DK2791675T3 (da) 2018-07-30
US9075069B2 (en) 2015-07-07
AR089233A1 (es) 2014-08-06
AU2012321074A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
AU2012321074B2 (en) Measurement of autoantibodies at low conductivity conditions with increased sensitivity
Fialová et al. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis
BR112012014060B1 (pt) método para o diagnóstico da doença de alzheimer em um sujeito, para detecção da disfunção cognitiva branda ou para diferenciar a doença de alzheimer da disfunção cognitiva branda
US9115190B2 (en) Sequences, antibodies, methods and kits for detection and in vitro assay of periostin, in order to provide a diagnosis, follow-up or prognosis of diseases and biological phenomena involving periostin
WO2012099576A1 (en) Measurement of anti-amyloid antibodies in human blood
US20120183527A1 (en) Measurement of anti-amyloid antibodies in human blood
US20160370385A1 (en) Assay for anti-mullerian hormone
US9945871B2 (en) Method for measuring the level of circulating inhibitory factor 1 protein in a subject measuring the level of circulating inhibitory factor 1 (IF1) protein in a subject
JP2019528239A (ja) 変形性関節症を診断するためのコムペプチドおよびそれに対する抗体
JP6141257B2 (ja) Ｃ１ｑ−アディポネクチン複合体及びその利用
JP4283812B2 (ja) 重症筋無力症の診断方法およびそのキット
JP5852433B2 (ja) ソルチリンによる動脈硬化の判定方法
EP3213075B1 (en) Diagnosis of an autoimmune disease using detection of antibodies directed against c5a-receptor
EP2477032A1 (en) Measurement of anti-amyloid antibodies in human blood
JP6923212B2 (ja) 動脈硬化性疾患の発症の予測因子および検査方法
JP4774513B2 (ja) 自己免疫疾患の診断剤及び診断方法
AU2011200191A1 (en) Measurement of anti-beta amyloid antibodies in human blood
CA2728605A1 (en) Measurement of anti-beta amyloid antibodies in human blood
Tessier et al. journal of biochemistry and laboratory medicine
JPWO2018016607A1 (ja) ＩｇＧ４関連疾患の検査方法
BRPI1105423A2 (pt) Métodos para detectar um anticorpo de alta avidez anti-amilóide presente em uma amostra biológica

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: BAXALTA GMBH; BAXALTA INCORPORATED

Free format text: FORMER APPLICANT(S): BAXTER HEALTHCARE S.A.; BAXTER INTERNATIONAL INC.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): BAXALTA GMBH; BAXALTA INCORPORATED